Risk of intraocular hemorrhage with new oral anticoagulants.

Talany, G; Guo, M; Etminan, M

Talany, G; Guo, M; Etminan, M.

Affiliation

Talany G; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Guo M; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Etminan M; Department of Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.

Eye (Lond) ; 31(4): 628-631, 2017 Apr.

Article in En | MEDLINE | ID: mdl-28009346

Subject(s)

Anticoagulants/adverse effects; Eye Hemorrhage/chemically induced; Ocular Hypertension/chemically induced; Stroke/prevention & control; Anticoagulants/administration & dosage; Anticoagulants/pharmacokinetics; Dabigatran/adverse effects; Dabigatran/pharmacokinetics; Eye Hemorrhage/prevention & control; Humans; Odds Ratio; Pyrazoles/adverse effects; Pyrazoles/pharmacokinetics; Pyridones/adverse effects; Pyridones/pharmacokinetics; Risk Factors; Rivaroxaban/adverse effects; Rivaroxaban/pharmacokinetics; Stroke/drug therapy; Warfarin/adverse effects; Warfarin/pharmacokinetics

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Eye Hemorrhage / Ocular Hypertension / Stroke / Anticoagulants Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Eye (Lond) Journal subject: OFTALMOLOGIA Year: 2017 Document type: Article Affiliation country: Canada

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google